VANDA PHARMACEUTICALS INC. (VNDA)

Every figure this model derived for VNDA, the value it took, and the element in the company's own XBRL it was read from — so any of it can be checked against the filing rather than taken on trust. As at 2026-06-30.

The figures, and where each came from

This is the part no other screener shows. Each figure below names the XBRL element it was read from, so it can be checked against the filing itself.

FigureValueXBRL tagAs at
capex 674,000 PaymentsToAcquirePropertyPlantAndEquipment 2026-06-30
cash 438,514,000 CashAndCashEquivalentsAtCarryingValue 2026-06-30
current assets 264,484,000 AssetsCurrent 2026-06-30
current liabilities 164,026,000 LiabilitiesCurrent 2026-06-30
equity 220,185,000 StockholdersEquity 2026-06-30
ocf -142,331,000 NetCashProvidedByUsedInOperatingActivities 2026-06-30
revenue 215,721,000 Revenues 2026-06-30
sbc 9,067,000 ShareBasedCompensation 2026-06-30

The ratios

The figures themselves rather than their scores — what somebody looking up VNDA on one particular measure came for.

RatioValue
cash operating margin-81.34
current ratio1.61
current ratio reported1.61
deferred revenue growth-99.35
dilution pct1.34
fcf margin-66.29
operating margin-86.07
owner earnings margin-70.49
revenue growth6.02
revenue growth per share4.62
rule of 40-80.05
sbc pct revenue4.2

What to be careful about

What this model itself distrusts about VNDA's figures. Written by the derivation as it ran, not added afterwards.